Qing Li, Yinong Chen, Lu Yu, Long-yang Zhu, Zhe Wang, Si-qi Jiao, Shuwen Zheng, Yihong Sun
Background: Women with atrial fibrillation (AF) have poorer quality of life (QoL) than men; however, the factors contributing to the poorer QoL in women is unclear. Methods: We analyzed data for 3562 patients with non-valvular AF enrolled in the China Registry of Atrial Fibrillation. The Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) was used to evaluate QoL, which was compared between women and men. A multivariate logistic regression analysis model was used to explore factors potentially explaining the sex difference in QoL. Results: Overall, 43.3% of the cohort comprised women (n=1541) who were older than their male counterparts (72 ± 9.8 vs. 68 ± 11.9 years, P<0.001). Compared with men, women were more likely to have more symptoms, hypertension, diabetes mellitus, and heart failure. Women were less likely than men to receive catheter ablation (4.5% vs. 6.1%, P=0.044). Women also had lower physical component summary (PCS) scores (48 ± 9 vs. 51 ± 9, P<0.001) and mental component summary (MCS) scores (49 ± 10 vs. 51 ± 10, P<0.001) than men. In the multivariable analysis of the poorer PCS scores in women, patient age explained 32.9%, low socioeconomic status explained 20.0%, lifestyle explained 14.3%, cardiovascular comorbidities explained 15.7%, the presence of more symptoms explained 5.7%, and less catheter ablation explained 1.4%. These factors also explained similar proportions of the sex difference in MCS scores. Together, these factors explained 54.3% of the poorer physical function status and 46.8% of the poorer mental function status in women than men. Conclusions: Women with AF had poorer QoL than men. The following factors partly explained the poorer QoL in women: older age, low level of socioeconomic status, more cardiovascular comorbidities, less smoking and drinking, more symptoms, and less catheter ablation.
{"title":"Sex Differences in Quality of Life and their Explanatory Variables in Patients with Non-Valvular Atrial Fibrillation","authors":"Qing Li, Yinong Chen, Lu Yu, Long-yang Zhu, Zhe Wang, Si-qi Jiao, Shuwen Zheng, Yihong Sun","doi":"10.15212/cvia.2023.0017","DOIUrl":"https://doi.org/10.15212/cvia.2023.0017","url":null,"abstract":"\u0000Background: Women with atrial fibrillation (AF) have poorer quality of life (QoL) than men; however, the factors contributing to the poorer QoL in women is unclear.\u0000\u0000Methods: We analyzed data for 3562 patients with non-valvular AF enrolled in the China Registry of Atrial Fibrillation. The Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) was used to evaluate QoL, which was compared between women and men. A multivariate logistic regression analysis model was used to explore factors potentially explaining the sex difference in QoL.\u0000\u0000Results: Overall, 43.3% of the cohort comprised women (n=1541) who were older than their male counterparts (72 ± 9.8 vs. 68 ± 11.9 years, P<0.001). Compared with men, women were more likely to have more symptoms, hypertension, diabetes mellitus, and heart failure. Women were less likely than men to receive catheter ablation (4.5% vs. 6.1%, P=0.044). Women also had lower physical component summary (PCS) scores (48 ± 9 vs. 51 ± 9, P<0.001) and mental component summary (MCS) scores (49 ± 10 vs. 51 ± 10, P<0.001) than men. In the multivariable analysis of the poorer PCS scores in women, patient age explained 32.9%, low socioeconomic status explained 20.0%, lifestyle explained 14.3%, cardiovascular comorbidities explained 15.7%, the presence of more symptoms explained 5.7%, and less catheter ablation explained 1.4%. These factors also explained similar proportions of the sex difference in MCS scores. Together, these factors explained 54.3% of the poorer physical function status and 46.8% of the poorer mental function status in women than men.\u0000\u0000Conclusions: Women with AF had poorer QoL than men. The following factors partly explained the poorer QoL in women: older age, low level of socioeconomic status, more cardiovascular comorbidities, less smoking and drinking, more symptoms, and less catheter ablation.","PeriodicalId":41559,"journal":{"name":"Cardiovascular Innovations and Applications","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44135092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Dilated cardiomyopathy (DCM) is a non-ischemic heart disease that poses a substantial global health burden, but its underlying molecular mechanisms remain poorly understood. Methods: Weighted gene co-expression network analysis, differential expression analysis of genes, enriched analysis and LASSO model construction were performed in R software. miRWalk 2.0 and StarBase v2.0 were used to predict the target miRNAs and circRNAs of hub genes, respectively. Results: Four hub genes (COL3A1, COL1A2, LUM and THBS4) were identified, which were significantly enriched in fibrosis pathways, including extracellular matrix, biological process, and the TGF beta signaling and focal adhesion pathways. The LASSO model accurately predicted the occurrence of DCM. Additionally, three miRNAs (hsa-let-7b-5p, hsa-let-7c-5p and hsa-miR-29b-3p) and 30 circRNAs (including GIT2_hsa_circRNA10114, ANKRD52_hsa_circRNA9983 and JARID2_hsa_circRNA6618) were found to be associated with DCM. Conclusion: Bioinformatics analysis identified hub genes and related molecules that may be highly associated with DCM. These findings provide insights into potential targets for improving diagnosis and pharmacological therapies to prevent DCM progression.
{"title":"Identifying Key Genes and Related Molecules as Potential Biomarkers in Human Dilated Cardiomyopathy by Comprehensive Bioinformatics Analysis","authors":"Yingrui Li, Jianlin Du, Bin Liu, Q. She","doi":"10.15212/cvia.2023.0018","DOIUrl":"https://doi.org/10.15212/cvia.2023.0018","url":null,"abstract":"\u0000Background: Dilated cardiomyopathy (DCM) is a non-ischemic heart disease that poses a substantial global health burden, but its underlying molecular mechanisms remain poorly understood.\u0000\u0000Methods: Weighted gene co-expression network analysis, differential expression analysis of genes, enriched analysis and LASSO model construction were performed in R software. miRWalk 2.0 and StarBase v2.0 were used to predict the target miRNAs and circRNAs of hub genes, respectively.\u0000\u0000Results: Four hub genes (COL3A1, COL1A2, LUM and THBS4) were identified, which were significantly enriched in fibrosis pathways, including extracellular matrix, biological process, and the TGF beta signaling and focal adhesion pathways. The LASSO model accurately predicted the occurrence of DCM. Additionally, three miRNAs (hsa-let-7b-5p, hsa-let-7c-5p and hsa-miR-29b-3p) and 30 circRNAs (including GIT2_hsa_circRNA10114, ANKRD52_hsa_circRNA9983 and JARID2_hsa_circRNA6618) were found to be associated with DCM.\u0000\u0000Conclusion: Bioinformatics analysis identified hub genes and related molecules that may be highly associated with DCM. These findings provide insights into potential targets for improving diagnosis and pharmacological therapies to prevent DCM progression.","PeriodicalId":41559,"journal":{"name":"Cardiovascular Innovations and Applications","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49074718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fuding Guo, Jun Wang, Liping Zhou, Yue Wang, Hong Jiang, Lilei Yu
The increased application of catheter ablation to treat cardiac arrhythmias has contributed to continued exploration of safe and effective tissue ablation tools in the field of electrophysiology. Pulsed field ablation (PFA), a novel recently developed non-thermal energy-based technique, uses trains of microsecond duration high-amplitude pulses to ablate target cells. Several preclinical and clinical studies have demonstrated that PFA is a promising tool for cardiac ablation to treat arrhythmia. In addition to being an effective tissue ablation technique, PFA is safe, because it avoids damage to the surrounding cells/tissues. This review focuses on efficacy and safety outcomes reported in preclinical and clinical studies evaluating the effects of PFA on arrhythmia, and discusses limitations and potential future directions of PFA.
{"title":"Advances in the Application of Pulsed Field Ablation for Arrhythmia Treatment","authors":"Fuding Guo, Jun Wang, Liping Zhou, Yue Wang, Hong Jiang, Lilei Yu","doi":"10.15212/cvia.2023.0019","DOIUrl":"https://doi.org/10.15212/cvia.2023.0019","url":null,"abstract":"The increased application of catheter ablation to treat cardiac arrhythmias has contributed to continued exploration of safe and effective tissue ablation tools in the field of electrophysiology. Pulsed field ablation (PFA), a novel recently developed non-thermal energy-based technique, uses trains of microsecond duration high-amplitude pulses to ablate target cells. Several preclinical and clinical studies have demonstrated that PFA is a promising tool for cardiac ablation to treat arrhythmia. In addition to being an effective tissue ablation technique, PFA is safe, because it avoids damage to the surrounding cells/tissues. This review focuses on efficacy and safety outcomes reported in preclinical and clinical studies evaluating the effects of PFA on arrhythmia, and discusses limitations and potential future directions of PFA.","PeriodicalId":41559,"journal":{"name":"Cardiovascular Innovations and Applications","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41319656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rongrong Shen, Peiyu Zhang, Jing Liu, Rong Guo, Yawei Xu
Background/aim: This study was aimed at evaluating 5-year effectiveness and safety in participants after XIENCE PRIME Everolimus Elution Coronary Stent System (EECSS) implantation. Materials and methods: From December 2013 to May 2014, 108 patients (127 lesions) were treated with the XIENCE PRIME EECSS. The entire follow-up included annual assessments for 5 years after treatment or until one of the clinical endpoints was reached. We evaluated the 5-year clinical outcomes with Kaplan-Meier analysis and the Cox regression model. Results: Nearly three-quarters of the participants were men (76.8%), and the average age was 65.6 ± 10.8 years. Bifurcation lesions accounted for 96.1% (122 lesions), and left main lesions accounted for 3.9% (five lesions), with a total count of 127 lesions. The cumulative rate of major adverse cardiac events was as follows: 1 year, 1.9%; 2 year, 4.0%; and 5 year, 10.0%. No definite or probable stent thrombosis was observed, and the rate of target lesion failure was only 3.3% over 5 years. The cumulative rate of major bleeding eventually increased to only 4.4%. Conclusions: The 5-year clinical outcomes were favorable in patients treated with XIENCE PRIME EECSS, and the incidence of stent thrombosis and target lesion failure was relatively low. The incidence of major bleeding gradually increased but remained moderate.
背景/目的：本研究旨在评估XIENCE PRIME依维莫司洗脱冠状动脉支架系统（EECSS）植入后参与者的5年有效性和安全性。材料和方法：从2013年12月到2014年5月，108名患者（127个病灶）接受了XIENCE PRIME EECSS治疗。整个随访包括治疗后5年或达到其中一个临床终点之前的年度评估。我们使用Kaplan-Meier分析和Cox回归模型评估了5年的临床结果。结果：近四分之三的参与者是男性（76.8%），平均年龄为65.6±10.8岁。分叉病变占96.1%（122个），左主干病变占3.9%（5个），总数127个。主要心脏不良事件的累计发生率如下：1年，1.9%；2年，4.0%；5年，10.0%。未观察到明确或可能的支架血栓形成，5年内靶病变失败率仅为3.3%。大出血的累积率最终仅增加到4.4%。结论：XIENCE PRIME EECSS治疗的患者5年临床结果良好，支架血栓形成和靶病变失败的发生率相对较低。大出血的发生率逐渐增加，但仍为中度。
{"title":"Five-Year Clinical Outcomes After XIENCE PRIME Everolimus Elution Coronary Stent System (EECSS) Implantation","authors":"Rongrong Shen, Peiyu Zhang, Jing Liu, Rong Guo, Yawei Xu","doi":"10.15212/cvia.2023.0013","DOIUrl":"https://doi.org/10.15212/cvia.2023.0013","url":null,"abstract":"\u0000Background/aim: This study was aimed at evaluating 5-year effectiveness and safety in participants after XIENCE PRIME Everolimus Elution Coronary Stent System (EECSS) implantation.\u0000\u0000Materials and methods: From December 2013 to May 2014, 108 patients (127 lesions) were treated with the XIENCE PRIME EECSS. The entire follow-up included annual assessments for 5 years after treatment or until one of the clinical endpoints was reached. We evaluated the 5-year clinical outcomes with Kaplan-Meier analysis and the Cox regression model.\u0000\u0000Results: Nearly three-quarters of the participants were men (76.8%), and the average age was 65.6 ± 10.8 years. Bifurcation lesions accounted for 96.1% (122 lesions), and left main lesions accounted for 3.9% (five lesions), with a total count of 127 lesions. The cumulative rate of major adverse cardiac events was as follows: 1 year, 1.9%; 2 year, 4.0%; and 5 year, 10.0%. No definite or probable stent thrombosis was observed, and the rate of target lesion failure was only 3.3% over 5 years. The cumulative rate of major bleeding eventually increased to only 4.4%.\u0000\u0000Conclusions: The 5-year clinical outcomes were favorable in patients treated with XIENCE PRIME EECSS, and the incidence of stent thrombosis and target lesion failure was relatively low. The incidence of major bleeding gradually increased but remained moderate.","PeriodicalId":41559,"journal":{"name":"Cardiovascular Innovations and Applications","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42667400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pulsed field ablation (PFA), a promising technology for ablating arrhythmias, has significantly better efficiency and potentially greater safety than traditional ablation techniques using thermal injury. However, most clinical research on PFA for ablation to date has used basket- or flower-shaped catheters, thus requiring a large introducing sheath and catheter location under fluoroscopic guidance. Herein, we describe our initial experience in using a three-dimensional PFA system integrating mapping and ablation, and an annular catheter.
{"title":"Experience in Application of a Three-Dimensional Pulsed Field Ablation System Integrating Mapping and Ablation","authors":"Yan Wang, Jie Qiu, Daowen Wang","doi":"10.15212/cvia.2023.0009","DOIUrl":"https://doi.org/10.15212/cvia.2023.0009","url":null,"abstract":"Pulsed field ablation (PFA), a promising technology for ablating arrhythmias, has significantly better efficiency and potentially greater safety than traditional ablation techniques using thermal injury. However, most clinical research on PFA for ablation to date has used basket- or flower-shaped catheters, thus requiring a large introducing sheath and catheter location under fluoroscopic guidance. Herein, we describe our initial experience in using a three-dimensional PFA system integrating mapping and ablation, and an annular catheter.","PeriodicalId":41559,"journal":{"name":"Cardiovascular Innovations and Applications","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48898344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bin Xiong, Shaojie Chen, Weijie Chen, Y. Yin, Zhiyu Ling
Hypertension significantly increases the risk of cardiovascular events and it is associated with high rates of disability and mortality. Hypertension is a common cause of cardiovascular and cerebrovascular accidents, which severely affect patients’ quality of life and lifespan. Current treatment strategies for hypertension are based primarily on medication and lifestyle interventions. The renal sympathetic nervous system plays an important role in the pathogenesis of hypertension, and catheter-based renal denervation (RDN) has provided a new concept for the treatment of hypertension. In recent years, studies on RDN have been performed worldwide. This article reviews the latest preclinical research and clinical evidence for RDN.
{"title":"Advances in Renal Denervation in the Treatment of Hypertension","authors":"Bin Xiong, Shaojie Chen, Weijie Chen, Y. Yin, Zhiyu Ling","doi":"10.15212/cvia.2023.0014","DOIUrl":"https://doi.org/10.15212/cvia.2023.0014","url":null,"abstract":"Hypertension significantly increases the risk of cardiovascular events and it is associated with high rates of disability and mortality. Hypertension is a common cause of cardiovascular and cerebrovascular accidents, which severely affect patients’ quality of life and lifespan. Current treatment strategies for hypertension are based primarily on medication and lifestyle interventions. The renal sympathetic nervous system plays an important role in the pathogenesis of hypertension, and catheter-based renal denervation (RDN) has provided a new concept for the treatment of hypertension. In recent years, studies on RDN have been performed worldwide. This article reviews the latest preclinical research and clinical evidence for RDN.","PeriodicalId":41559,"journal":{"name":"Cardiovascular Innovations and Applications","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47686420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jiawei Zhou, Dongfang You, Jianling Bai, Xin Chen, Yaqian Wu, Zhongtian Wang, Yingdan Tang, Yang Zhao, G. Feng
Objective: Cardiovascular disease (CVD) is one of the leading causes of death worldwide, and answers are urgently needed regarding many aspects, particularly risk identification and prognosis prediction. Real-world studies with large numbers of observations provide an important basis for CVD research but are constrained by high dimensionality, and missing or unstructured data. Machine learning (ML) methods, including a variety of supervised and unsupervised algorithms, are useful for data governance, and are effective for high dimensional data analysis and imputation in real-world studies. This article reviews the theory, strengths and limitations, and applications of several commonly used ML methods in the CVD field, to provide a reference for further application. Methods: This article introduces the origin, purpose, theory, advantages and limitations, and applications of multiple commonly used ML algorithms, including hierarchical and k-means clustering, principal component analysis, random forest, support vector machine, and neural networks. An example uses a random forest on the Systolic Blood Pressure Intervention Trial (SPRINT) data to demonstrate the process and main results of ML application in CVD. Conclusion: ML methods are effective tools for producing real-world evidence to support clinical decisions and meet clinical needs. This review explains the principles of multiple ML methods in plain language, to provide a reference for further application. Future research is warranted to develop accurate ensemble learning methods for wide application in the medical field.
{"title":"Machine Learning Methods in Real-World Studies of Cardiovascular Disease","authors":"Jiawei Zhou, Dongfang You, Jianling Bai, Xin Chen, Yaqian Wu, Zhongtian Wang, Yingdan Tang, Yang Zhao, G. Feng","doi":"10.15212/cvia.2023.0011","DOIUrl":"https://doi.org/10.15212/cvia.2023.0011","url":null,"abstract":"\u0000Objective: Cardiovascular disease (CVD) is one of the leading causes of death worldwide, and answers are urgently needed regarding many aspects, particularly risk identification and prognosis prediction. Real-world studies with large numbers of observations provide an important basis for CVD research but are constrained by high dimensionality, and missing or unstructured data. Machine learning (ML) methods, including a variety of supervised and unsupervised algorithms, are useful for data governance, and are effective for high dimensional data analysis and imputation in real-world studies. This article reviews the theory, strengths and limitations, and applications of several commonly used ML methods in the CVD field, to provide a reference for further application.\u0000\u0000Methods: This article introduces the origin, purpose, theory, advantages and limitations, and applications of multiple commonly used ML algorithms, including hierarchical and k-means clustering, principal component analysis, random forest, support vector machine, and neural networks. An example uses a random forest on the Systolic Blood Pressure Intervention Trial (SPRINT) data to demonstrate the process and main results of ML application in CVD.\u0000\u0000Conclusion: ML methods are effective tools for producing real-world evidence to support clinical decisions and meet clinical needs. This review explains the principles of multiple ML methods in plain language, to provide a reference for further application. Future research is warranted to develop accurate ensemble learning methods for wide application in the medical field.","PeriodicalId":41559,"journal":{"name":"Cardiovascular Innovations and Applications","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46885057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Atrial fibrillation (AF) is a common complication of coronary revascularization. Currently, the mechanisms of postoperative AF are unclear. This study was aimed at investigating the risk factors for new-onset AF (NOAF) after coronary revascularization and exploring the early warning effects of clinical inflammatory markers. A retrospective analysis was conducted on 293 patients with unstable angina pectoris who underwent coronary artery revascularization in Beijing Chao-Yang Hospital, Capital Medical University, between April 2018 and June 2021, including 224 patients who underwent coronary artery bypass grafting and 69 patients who underwent one-step hybrid coronary revascularization. Baseline data, clinical data, blood indicators and AF episodes within 7 days after the surgery were collected. Participants were divided into two groups according to whether AF occurred, and the data were analyzed between groups. In addition, multivariate logistic regression was used to explore the independent risk factors for developing AF post coronary revascularization. Aging, a larger left atrial inferior-superior diameter, use of an intra-aortic balloon pump, a greater blood volume transfused during perioperative period and a higher monocyte to high-density lipoprotein ratios on postoperative day 1 were independent risk factors for NOAF after coronary artery surgery.
{"title":"Elevated Monocyte to High-density Lipoprotein Ratio Is a Risk Factor for New-onset Atrial Fibrillation after Off-pump Coronary Revascularization","authors":"Yameng Mu, Jiayin Niu, Min Zhang, Pengfei Liu, Cuncun Hua, Yulin Guo, Guangzhen Zhong","doi":"10.15212/cvia.2023.0012","DOIUrl":"https://doi.org/10.15212/cvia.2023.0012","url":null,"abstract":"Atrial fibrillation (AF) is a common complication of coronary revascularization. Currently, the mechanisms of postoperative AF are unclear. This study was aimed at investigating the risk factors for new-onset AF (NOAF) after coronary revascularization and exploring the early warning effects of clinical inflammatory markers. A retrospective analysis was conducted on 293 patients with unstable angina pectoris who underwent coronary artery revascularization in Beijing Chao-Yang Hospital, Capital Medical University, between April 2018 and June 2021, including 224 patients who underwent coronary artery bypass grafting and 69 patients who underwent one-step hybrid coronary revascularization. Baseline data, clinical data, blood indicators and AF episodes within 7 days after the surgery were collected. Participants were divided into two groups according to whether AF occurred, and the data were analyzed between groups. In addition, multivariate logistic regression was used to explore the independent risk factors for developing AF post coronary revascularization. Aging, a larger left atrial inferior-superior diameter, use of an intra-aortic balloon pump, a greater blood volume transfused during perioperative period and a higher monocyte to high-density lipoprotein ratios on postoperative day 1 were independent risk factors for NOAF after coronary artery surgery.","PeriodicalId":41559,"journal":{"name":"Cardiovascular Innovations and Applications","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47394704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bo Zhang, Shuhan Li, Han Liu, Dongze Wang, Ang Gao, Yihan Wang, Zhiyuan Gao, Tongyu Hou, Qian Xu
Aims: In this study, we aimed to identify cuproptosis-associated ferroptosis genes in the atherosclerosis microarray of the Gene Expression Omnibus (GEO) database and to explore hub gene-mediated immune infiltration in atherosclerosis. Background: Immune infiltration plays a crucial role in atherosclerosis development. Ferroptosis is a mode of cell death caused by the iron-dependent accumulation of lipid peroxides. Cuproptosis is a recently discovered type of programmed cell death. No previous studies have examined the mechanism of cuproptosis-associated ferroptosis gene regulation in immune infiltration in atherosclerosis. Methods: We searched the qualified atherosclerosis gene microarray in the GEO database, integrated it with ferroptosis and cuproptosis genes, and calculated the correlation coefficients. We then obtained the cuproptosis-associated ferroptosis gene matrix and screened differentially expressed genes. Subsequently, we performed Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses and protein–protein interaction network analysis of differentially expressed genes. We also screened hub genes according to the Matthews correlation coefficient (MCC) algorithm. We conducted enrichment analysis of hub genes to explore their functions and predict related microRNAs (P<0.05). We also used the single-sample gene set enrichment analysis (ssGSEA) algorithm to analyze the relationships between hub genes and immune infiltration, and used immune-associated hub genes to construct a risk model. Finally, we used the drug prediction results and molecular docking technology to explore potential therapeutic drugs targeting the hub genes. Results: Seventy-eight cuproptosis-associated ferroptosis genes were found to be involved in the cellular response to oxidative and chemical stress, and to be enriched in multiple pathways, including ferroptosis, glutathione metabolism, and atherosclerosis. Ten hub genes were identified with the MCC algorithm; according to the ssGSEA algorithm, these genes were closely associated with immune infiltration, thus indicating that cuproptosis-associated ferroptosis genes may participate in atherosclerosis by mediating immune infiltration. The receiver operating characteristic curve indicated that the model had a good ability to predict atherosclerosis risk. The results of drug prediction (adjusted P<0.001) and molecular docking showed that glutathione may be a potential therapeutic drug that targets the hub genes. Conclusion: Cuproptosis-associated ferroptosis genes are associated with immune infiltration in atherosclerosis.
{"title":"Immune Infiltration in Atherosclerosis is Mediated by Cuproptosis-Associated Ferroptosis Genes","authors":"Bo Zhang, Shuhan Li, Han Liu, Dongze Wang, Ang Gao, Yihan Wang, Zhiyuan Gao, Tongyu Hou, Qian Xu","doi":"10.15212/cvia.2023.0003","DOIUrl":"https://doi.org/10.15212/cvia.2023.0003","url":null,"abstract":"Aims: In this study, we aimed to identify cuproptosis-associated ferroptosis genes in the atherosclerosis microarray of the Gene Expression Omnibus (GEO) database and to explore hub gene-mediated immune infiltration in atherosclerosis. Background: Immune infiltration plays a crucial role in atherosclerosis development. Ferroptosis is a mode of cell death caused by the iron-dependent accumulation of lipid peroxides. Cuproptosis is a recently discovered type of programmed cell death. No previous studies have examined the mechanism of cuproptosis-associated ferroptosis gene regulation in immune infiltration in atherosclerosis. Methods: We searched the qualified atherosclerosis gene microarray in the GEO database, integrated it with ferroptosis and cuproptosis genes, and calculated the correlation coefficients. We then obtained the cuproptosis-associated ferroptosis gene matrix and screened differentially expressed genes. Subsequently, we performed Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses and protein–protein interaction network analysis of differentially expressed genes. We also screened hub genes according to the Matthews correlation coefficient (MCC) algorithm. We conducted enrichment analysis of hub genes to explore their functions and predict related microRNAs (P<0.05). We also used the single-sample gene set enrichment analysis (ssGSEA) algorithm to analyze the relationships between hub genes and immune infiltration, and used immune-associated hub genes to construct a risk model. Finally, we used the drug prediction results and molecular docking technology to explore potential therapeutic drugs targeting the hub genes. Results: Seventy-eight cuproptosis-associated ferroptosis genes were found to be involved in the cellular response to oxidative and chemical stress, and to be enriched in multiple pathways, including ferroptosis, glutathione metabolism, and atherosclerosis. Ten hub genes were identified with the MCC algorithm; according to the ssGSEA algorithm, these genes were closely associated with immune infiltration, thus indicating that cuproptosis-associated ferroptosis genes may participate in atherosclerosis by mediating immune infiltration. The receiver operating characteristic curve indicated that the model had a good ability to predict atherosclerosis risk. The results of drug prediction (adjusted P<0.001) and molecular docking showed that glutathione may be a potential therapeutic drug that targets the hub genes. Conclusion: Cuproptosis-associated ferroptosis genes are associated with immune infiltration in atherosclerosis.","PeriodicalId":41559,"journal":{"name":"Cardiovascular Innovations and Applications","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48877775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: The study aimed to evaluate the role of the neutrophil percentage (N%) at admission in predicting in-hospital major adverse cardiovascular events (MACE) in patients ≥75 years of age with acute coronary syndrome (ACS). Methods: A total of 1189 patients above 75 years of age with ACS hospitalized at the Second Xiangya Hospital between January 2013 and December 2017 were enrolled in this retrospective study. Receiver operator characteristic curve analysis was performed to calculate the optimal N% cut-off value for patient grouping. The in-hospital MACE consisted of acute left heart failure, stroke and any cause of death. Multivariable logistic analyses were used to assess the role of N% in predicting MACE in older patients with ACS. Results: The patients were divided into a high N% group (N% ≥74.17%, n=396) and low N% group (N%<74.17%, n=793) according to the N% cut-off value (N%=74.17%). The rate of MACEs during hospitalization was considerably higher in the high N% group than the low N% group (27.5% vs. 9.6%, P<0.001). After adjustment for other factors, high N% remained an independent risk factor for in-hospital MACE in older patients with ACS (odds ratio 1.779, 95% confidence interval 1.091–2.901, P=0.021). Conclusion: High N% at admission is an independent risk factor for in-hospital MACE in patients above 75 years of age with ACS.
{"title":"Association between Percentage of Neutrophils at Admission and in-Hospital Events in Patients ≥75 Years of Age with Acute Coronary Syndrome","authors":"Cuihong Tian, Zhaowei Zhu, Hebin Xie, Cheng Wei, Z. Fang, Xinqun Hu, Shenghua Zhou","doi":"10.15212/cvia.2023.0010","DOIUrl":"https://doi.org/10.15212/cvia.2023.0010","url":null,"abstract":"\u0000Objective: The study aimed to evaluate the role of the neutrophil percentage (N%) at admission in predicting in-hospital major adverse cardiovascular events (MACE) in patients ≥75 years of age with acute coronary syndrome (ACS).\u0000\u0000Methods: A total of 1189 patients above 75 years of age with ACS hospitalized at the Second Xiangya Hospital between January 2013 and December 2017 were enrolled in this retrospective study. Receiver operator characteristic curve analysis was performed to calculate the optimal N% cut-off value for patient grouping. The in-hospital MACE consisted of acute left heart failure, stroke and any cause of death. Multivariable logistic analyses were used to assess the role of N% in predicting MACE in older patients with ACS.\u0000\u0000Results: The patients were divided into a high N% group (N% ≥74.17%, n=396) and low N% group (N%<74.17%, n=793) according to the N% cut-off value (N%=74.17%). The rate of MACEs during hospitalization was considerably higher in the high N% group than the low N% group (27.5% vs. 9.6%, P<0.001). After adjustment for other factors, high N% remained an independent risk factor for in-hospital MACE in older patients with ACS (odds ratio 1.779, 95% confidence interval 1.091–2.901, P=0.021).\u0000\u0000Conclusion: High N% at admission is an independent risk factor for in-hospital MACE in patients above 75 years of age with ACS.","PeriodicalId":41559,"journal":{"name":"Cardiovascular Innovations and Applications","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45867799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：